Janney Montgomery Scott LLC raised its position in Core Laboratories N.V. (NYSE:CLB) by 2.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,676 shares of the oil and gas company’s stock after buying an additional 309 shares during the period. Janney Montgomery Scott LLC’s holdings in Core Laboratories N.V. were worth $1,182,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Congress Asset Management Co. MA raised its stake in shares of Core Laboratories N.V. by 8.8% in the second quarter. Congress Asset Management Co. MA now owns 558,762 shares of the oil and gas company’s stock worth $56,586,000 after buying an additional 45,258 shares in the last quarter. Howland Capital Management LLC raised its stake in shares of Core Laboratories N.V. by 0.8% in the second quarter. Howland Capital Management LLC now owns 106,874 shares of the oil and gas company’s stock worth $10,823,000 after buying an additional 883 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of Core Laboratories N.V. by 5.3% in the second quarter. Russell Investments Group Ltd. now owns 808,998 shares of the oil and gas company’s stock worth $81,935,000 after buying an additional 41,026 shares in the last quarter. Cue Financial Group Inc. raised its stake in shares of Core Laboratories N.V. by 11.0% in the second quarter. Cue Financial Group Inc. now owns 2,525 shares of the oil and gas company’s stock worth $256,000 after buying an additional 250 shares in the last quarter. Finally, Forsta AP Fonden purchased a new stake in shares of Core Laboratories N.V. during the second quarter worth about $15,674,000.

Core Laboratories N.V. (CLB) opened at 92.92 on Friday. The company has a market capitalization of $4.10 billion, a P/E ratio of 57.01 and a beta of 1.60. Core Laboratories N.V. has a 1-year low of $92.81 and a 1-year high of $125.83. The firm has a 50-day moving average price of $101.46 and a 200-day moving average price of $108.84.

Core Laboratories N.V. (NYSE:CLB) last issued its quarterly earnings data on Monday, July 24th. The oil and gas company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.51 by $0.01. The firm had revenue of $163.90 million during the quarter, compared to the consensus estimate of $168.23 million. Core Laboratories N.V. had a return on equity of 49.29% and a net margin of 11.80%. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.35 earnings per share. On average, analysts forecast that Core Laboratories N.V. will post $2.09 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 14th. Stockholders of record on Monday, July 17th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 2.37%. The ex-dividend date is Thursday, July 13th. Core Laboratories N.V.’s dividend payout ratio is presently 134.15%.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.watchlistnews.com/core-laboratories-n-v-clb-shares-bought-by-janney-montgomery-scott-llc/1476678.html.

CLB has been the topic of a number of recent research reports. BidaskClub lowered Core Laboratories N.V. from a “hold” rating to a “sell” rating in a research report on Saturday, June 24th. Loop Capital raised Core Laboratories N.V. from a “hold” rating to a “buy” rating and lifted their target price for the company from $125.00 to $130.00 in a research report on Friday, April 21st. Morgan Stanley reissued an “overweight” rating and issued a $130.00 target price (down previously from $150.00) on shares of Core Laboratories N.V. in a research report on Wednesday, June 21st. Piper Jaffray Companies set a $97.00 target price on Core Laboratories N.V. and gave the company a “hold” rating in a research report on Wednesday, July 26th. Finally, Zacks Investment Research lowered Core Laboratories N.V. from a “buy” rating to a “hold” rating in a research report on Friday, June 23rd. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $117.17.

About Core Laboratories N.V.

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.